u hv to be disciplined if u wa

1
Comment
Favorite

u hv to be disciplined if u want to lose weight. why so difficult?

Taking the new Wegovy pill every day is really complicated. Will patients stick with it?

'It's not an easy pill to take': The first highly anticipated GLP-1 pill is here, but physicians aren't sure it has the staying power of the injections. Once you take the Wegovy pill in the morning, you have to wait 30 minutes before eating or drinking anything.Patients are thrilled that there's finally a GLP-1 pill, but swallowing one is not as simple as it seems.Taking Novo Nordisk's Wegovy pill is an exacting process. You have to take it first thing in the morning, on an empty stomach, with no more than half a cup of water. Then you wait 30 minutes before eating breakfast, drinking coffee and other liquids, or taking other medications. You have to take the pill every day at the same time, and you must store it in the bottle .It's the first oral GLP-1 specifically approved for weight management. GLP-1 traditionally works best in an injection, but Novo Nordisk engineered the pill using technology that it acquired in 2020 to improve how well semaglutide - the medication's active ingre

Taking the new Wegovy pill every day is really complicated. Will patients stick with it?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":531413649756344,"tweetId":"531413649756344","gmtCreate":1770761207190,"gmtModify":1770761211446,"author":{"id":3568262728204718,"idStr":"3568262728204718","authorId":3568262728204718,"authorIdStr":"3568262728204718","name":"ICEsh00ter","avatar":"https://static.tigerbbs.com/e8d9d76c266e1d33abd00a525a8a445c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":93,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body>u hv to be disciplined if u want to lose weight. why so difficult?</body></html>","htmlText":"<html><head></head><body>u hv to be disciplined if u want to lose weight. why so difficult?</body></html>","text":"u hv to be disciplined if u want to lose weight. why so difficult?","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/531413649756344","repostId":2610675211,"repostType":2,"repost":{"id":"2610675211","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1770756480,"share":"https://ttm.financial/m/news/2610675211?lang=en_US&edition=fundamental","pubTime":"2026-02-11 04:48","market":"other","language":"en","title":"Taking the new Wegovy pill every day is really complicated. Will patients stick with it?","url":"https://stock-news.laohu8.com/highlight/detail?id=2610675211","media":"Dow Jones","summary":"'It's not an easy pill to take': The first highly anticipated GLP-1 pill is here, but physicians aren't sure it has the staying power of the injections. Once you take the Wegovy pill in the morning, you have to wait 30 minutes before eating or drinking anything.Patients are thrilled that there's finally a GLP-1 pill, but swallowing one is not as simple as it seems.Taking Novo Nordisk's Wegovy pill is an exacting process. You have to take it first thing in the morning, on an empty stomach, with no more than half a cup of water. Then you wait 30 minutes before eating breakfast, drinking coffee and other liquids, or taking other medications. You have to take the pill every day at the same time, and you must store it in the bottle .It's the first oral GLP-1 specifically approved for weight management. GLP-1 traditionally works best in an injection, but Novo Nordisk engineered the pill using technology that it acquired in 2020 to improve how well semaglutide - the medication's active ingre","content":"\n\nMW Taking the new Wegovy pill every day is really complicated. Will patients stick with it?\n\n\n By Jaimy Lee \n\n\n 'It's not an easy pill to take': The first highly anticipated GLP-1 pill is here, but physicians aren't sure it has the staying power of the injections \n\n\n Once you take the Wegovy pill in the morning, you have to wait 30 minutes before eating or drinking anything. \n\n\n Patients are thrilled that there's finally a GLP-1 pill, but swallowing one is not as simple as it seems. \n\n\n Taking <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s (NVO) Wegovy pill is an exacting process. You have to take it first thing in the morning, on an empty stomach, with no more than half a cup of water. Then you wait 30 minutes before eating breakfast, drinking coffee and other liquids, or taking other medications. You have to take the pill every day at the same time, and you must store it in the bottle (and not a pill box for travel). \n\n\n \"There's no other really big upside,\" said Diana Thiara, medical director of the University of California, San Francisco, Weight Management program. \"Why would you do something that's marginally less effective and not actually that much easier?\" \n\n\n The prevailing idea has been that a pill is easier to take, it's cheaper and it doesn't require refrigeration like Wegovy and Eli Lilly's <a href=\"https://laohu8.com/S/LLY\">$(LLY)$</a> Zepbound injections. It's also been pitched as an alternative to people who say they don't want to use an injector pen or a needle. \n\n\n But some physicians are skeptical that patients will stick with the Wegovy pill given the onerous daily regimen and comparable pricing to the Wegovy injection, especially if they end up not losing as much weight as they expect to. Instead of seeing a game-changer, these doctors view the Wegovy pill as another option in the toolbox that'll only work for certain patients. \n\n\n \"There's going to be a lot of patients that get a good benefit from it,\" said Scott Kahan, director of the National Center for Weight and Wellness in Chevy Chase, Md. \"There's also going to be quite a lot of patients that end up not using it, or try it and find the administration to be somewhat difficult, but that's OK.\" \n\n\n That said, the launch of the Wegovy pill is off to a roaring start. About 170,000 people in the U.S. had been prescribed the Wegovy pill by the first week in February, and \"most\" are paying directly for the medication, according to comments made by Novo's executives last week. Novo is charging $149 per month for the two lowest doses right now, and then the price goes up to $299 a month for the most effective doses. (The Wegovy injection costs $199 to start and then $349 to keep taking it.) \n\n\n It's the first oral GLP-1 specifically approved for weight management. GLP-1 traditionally works best in an injection, but Novo Nordisk engineered the pill using technology that it acquired in 2020 to improve how well semaglutide - the medication's active ingredient - is absorbed. \n\n\n \"This is not just a pill,\" Novo CEO Mike Doustdar said last week during an earnings call. \"It's a peptide. It's a large protein inside the pill that gives you that incredible efficacy.\" \n\n\n Demand is huge, and so are the marketing budgets. Two Super Bowl ads mentioned the Wegovy pill. Wall Street has breathlessly tracked weekly the pill's prescription volume, and the early numbers briefly lifted Novo's long-struggling stock in January. One analyst described it as the \"fastest launch ever.\" It's no wonder that Hims &amp; Hers Health <a href=\"https://laohu8.com/S/HIMS\">$(HIMS)$</a> rushed its own compounded version of the Wegovy pill to market before dropping those plans amid a legal dispute with Novo and U.S. regulators. \n\n\n Novo is facing its own clock. Lilly is gearing up to launch a new non-peptide GLP-1 pill that won't have the same administration restrictions as the Wegovy pill. Lilly also said last week that it will have a \"similar\" entry price. The Food and Drug Administration is set to decide whether to approve Lilly's orforglipron by sometime this summer. Novo Nordisk did not immediately respond to a request for comment. \n\n\n For now, patients are still trying to figure out if it's right for them. On <a href=\"https://laohu8.com/S/RDDT\">Reddit</a>, they are trading tips about how to handle the regimen, whether that's setting an early alarm, taking the pill, and going back to bed for 30 minutes, or asking how to relieve acid reflux from the pill if they do go back to bed. \n\n\n \"It's not an easy pill to take,\" said Scott Isaacs, an endocrinologist at Grady Memorial Hospital in Atlanta. \"It's this regime that can be onerous, and then when people learn about that, they say, 'Well, maybe taking a shot once a week is easier.'\" \n\n\n Novo sells another semaglutide pill called Rybelsus that's approved to treat type 2 diabetes with similar requirements around administration. Some experts are now taking a second look at that data to better understand what adherence to the Wegovy pill could look like. \n\n\n \"I do know - from my experience prescribing Rybelsus, which is basically the same thing for diabetes - it's hard to get patients to stay on it,\" Isaacs said. \"We see a lot of treatment failures, and when you assess why it's a treatment failure, most of the time it's because they're not taking the medication correctly.\" \n\n\n There is some data to back that up. The pharmacy benefit manager Prime <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> published a study in 2024 that found patients who did not have diabetes and started taking Rybelsus were far less adherent to the medication than those on Ozempic and Wegovy injections. (All three drugs are made with semaglutide as the main ingredient, though they are approved for different conditions and with different doses.) \n\n\n The research compared adherence rates for people starting eight GLP-1s in 2021, though it doesn't reflect some of the broader market dynamics at play that year. Wegovy wasn't approved until the middle of 2021, and Novo was dealing with major supply issues by the end of that year. \n\n\n In general, it can be harder for some patients to adhere to a daily pill rather than a weekly injection, experts say. Adherence rates are usually lower in real life than in the closely controlled environment of clinical trials. But some prefer a daily pill over a weekly injection. \n\n\n \"If people don't follow that very explicit requirement about how to take it, you will not get the extent of the drug absorption that you need to get the full effect,\" said Pat Gleason, Prime Therapeutics' assistant vice president of health outcomes. \"You're going to end up having stayed on [the] drug for six months, but you aren't getting your 10% body weight loss that you were told you were likely to get.\" \n\n\n The pill led to an average weight loss of 13.6% in clinical trials, while the Wegovy injection produced about 15% weight loss. \n\n\n Physicians expect they will need to switch some patients on the pill over to the injectable so they can get the weight loss they're looking for. \n\n\n \"We would have no reason to say no,\" UCSF's Thiara said. \n\n\n -Jaimy Lee \n\n\n This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n<pre style=\"white-space: pre\">\n \n</pre>\n\n (END) Dow Jones Newswires\n\n\n February 10, 2026 15:48 ET (20:48 GMT)\n\n\n Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n\n","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taking the new Wegovy pill every day is really complicated. Will patients stick with it?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaking the new Wegovy pill every day is really complicated. Will patients stick with it?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nDow Jones \n2026-02-11 04:48\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n\n\nMW Taking the new Wegovy pill every day is really complicated. Will patients stick with it?\n\n\n By Jaimy Lee \n\n\n 'It's not an easy pill to take': The first highly anticipated GLP-1 pill is here, but physicians aren't sure it has the staying power of the injections \n\n\n Once you take the Wegovy pill in the morning, you have to wait 30 minutes before eating or drinking anything. \n\n\n Patients are thrilled that there's finally a GLP-1 pill, but swallowing one is not as simple as it seems. \n\n\n Taking <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s (NVO) Wegovy pill is an exacting process. You have to take it first thing in the morning, on an empty stomach, with no more than half a cup of water. Then you wait 30 minutes before eating breakfast, drinking coffee and other liquids, or taking other medications. You have to take the pill every day at the same time, and you must store it in the bottle (and not a pill box for travel). \n\n\n \"There's no other really big upside,\" said Diana Thiara, medical director of the University of California, San Francisco, Weight Management program. \"Why would you do something that's marginally less effective and not actually that much easier?\" \n\n\n The prevailing idea has been that a pill is easier to take, it's cheaper and it doesn't require refrigeration like Wegovy and Eli Lilly's <a href=\"https://laohu8.com/S/LLY\">$(LLY)$</a> Zepbound injections. It's also been pitched as an alternative to people who say they don't want to use an injector pen or a needle. \n\n\n But some physicians are skeptical that patients will stick with the Wegovy pill given the onerous daily regimen and comparable pricing to the Wegovy injection, especially if they end up not losing as much weight as they expect to. Instead of seeing a game-changer, these doctors view the Wegovy pill as another option in the toolbox that'll only work for certain patients. \n\n\n \"There's going to be a lot of patients that get a good benefit from it,\" said Scott Kahan, director of the National Center for Weight and Wellness in Chevy Chase, Md. \"There's also going to be quite a lot of patients that end up not using it, or try it and find the administration to be somewhat difficult, but that's OK.\" \n\n\n That said, the launch of the Wegovy pill is off to a roaring start. About 170,000 people in the U.S. had been prescribed the Wegovy pill by the first week in February, and \"most\" are paying directly for the medication, according to comments made by Novo's executives last week. Novo is charging $149 per month for the two lowest doses right now, and then the price goes up to $299 a month for the most effective doses. (The Wegovy injection costs $199 to start and then $349 to keep taking it.) \n\n\n It's the first oral GLP-1 specifically approved for weight management. GLP-1 traditionally works best in an injection, but Novo Nordisk engineered the pill using technology that it acquired in 2020 to improve how well semaglutide - the medication's active ingredient - is absorbed. \n\n\n \"This is not just a pill,\" Novo CEO Mike Doustdar said last week during an earnings call. \"It's a peptide. It's a large protein inside the pill that gives you that incredible efficacy.\" \n\n\n Demand is huge, and so are the marketing budgets. Two Super Bowl ads mentioned the Wegovy pill. Wall Street has breathlessly tracked weekly the pill's prescription volume, and the early numbers briefly lifted Novo's long-struggling stock in January. One analyst described it as the \"fastest launch ever.\" It's no wonder that Hims &amp; Hers Health <a href=\"https://laohu8.com/S/HIMS\">$(HIMS)$</a> rushed its own compounded version of the Wegovy pill to market before dropping those plans amid a legal dispute with Novo and U.S. regulators. \n\n\n Novo is facing its own clock. Lilly is gearing up to launch a new non-peptide GLP-1 pill that won't have the same administration restrictions as the Wegovy pill. Lilly also said last week that it will have a \"similar\" entry price. The Food and Drug Administration is set to decide whether to approve Lilly's orforglipron by sometime this summer. Novo Nordisk did not immediately respond to a request for comment. \n\n\n For now, patients are still trying to figure out if it's right for them. On <a href=\"https://laohu8.com/S/RDDT\">Reddit</a>, they are trading tips about how to handle the regimen, whether that's setting an early alarm, taking the pill, and going back to bed for 30 minutes, or asking how to relieve acid reflux from the pill if they do go back to bed. \n\n\n \"It's not an easy pill to take,\" said Scott Isaacs, an endocrinologist at Grady Memorial Hospital in Atlanta. \"It's this regime that can be onerous, and then when people learn about that, they say, 'Well, maybe taking a shot once a week is easier.'\" \n\n\n Novo sells another semaglutide pill called Rybelsus that's approved to treat type 2 diabetes with similar requirements around administration. Some experts are now taking a second look at that data to better understand what adherence to the Wegovy pill could look like. \n\n\n \"I do know - from my experience prescribing Rybelsus, which is basically the same thing for diabetes - it's hard to get patients to stay on it,\" Isaacs said. \"We see a lot of treatment failures, and when you assess why it's a treatment failure, most of the time it's because they're not taking the medication correctly.\" \n\n\n There is some data to back that up. The pharmacy benefit manager Prime <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> published a study in 2024 that found patients who did not have diabetes and started taking Rybelsus were far less adherent to the medication than those on Ozempic and Wegovy injections. (All three drugs are made with semaglutide as the main ingredient, though they are approved for different conditions and with different doses.) \n\n\n The research compared adherence rates for people starting eight GLP-1s in 2021, though it doesn't reflect some of the broader market dynamics at play that year. Wegovy wasn't approved until the middle of 2021, and Novo was dealing with major supply issues by the end of that year. \n\n\n In general, it can be harder for some patients to adhere to a daily pill rather than a weekly injection, experts say. Adherence rates are usually lower in real life than in the closely controlled environment of clinical trials. But some prefer a daily pill over a weekly injection. \n\n\n \"If people don't follow that very explicit requirement about how to take it, you will not get the extent of the drug absorption that you need to get the full effect,\" said Pat Gleason, Prime Therapeutics' assistant vice president of health outcomes. \"You're going to end up having stayed on [the] drug for six months, but you aren't getting your 10% body weight loss that you were told you were likely to get.\" \n\n\n The pill led to an average weight loss of 13.6% in clinical trials, while the Wegovy injection produced about 15% weight loss. \n\n\n Physicians expect they will need to switch some patients on the pill over to the injectable so they can get the weight loss they're looking for. \n\n\n \"We would have no reason to say no,\" UCSF's Thiara said. \n\n\n -Jaimy Lee \n\n\n This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n<pre style=\"white-space: pre\">\n \n</pre>\n\n (END) Dow Jones Newswires\n\n\n February 10, 2026 15:48 ET (20:48 GMT)\n\n\n Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","HMYY":"GraniteShares YieldBoost HIMS ETF","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","SG9999015978.USD":"利安颠覆性创新基金A","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","NVO":"诺和诺德","BK4581":"高盛持仓","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU2063271972.USD":"富兰克林创新领域基金","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","BK4534":"瑞士信贷持仓","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443895.HKD":"abrdn SICAV I - GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4516":"特朗普概念","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0238689110.USD":"贝莱德环球动力股票基金","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LLY":"礼来","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4196":"保健护理服务","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","BK4585":"ETF&股票定投概念","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU2237443465.HKD":"abrdn SICAV I - GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0353189763.USD":"ALLSPRING US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4588":"碎股","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4599":"减肥药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0354030511.USD":"ALLSPRING U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","HIMY":"Defiance Leveraged Long + Income HIMS ETF","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","ELIL":"2倍做多LLY ETF-Direxion","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU2087625088.SGD":"ALLSPRING US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","ELIS":"1倍做空LLY ETF-Direxion","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LLYX":"2倍做多LLY ETF-Defiance","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LLYZ":"2倍做空LLY ETF-Defiance","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","NVOX":"2倍做多NVO ETF-Defiance","BK4007":"制药","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2610675211","content_text":"MW Taking the new Wegovy pill every day is really complicated. Will patients stick with it?\n\n\n By Jaimy Lee \n\n\n 'It's not an easy pill to take': The first highly anticipated GLP-1 pill is here, but physicians aren't sure it has the staying power of the injections \n\n\n Once you take the Wegovy pill in the morning, you have to wait 30 minutes before eating or drinking anything. \n\n\n Patients are thrilled that there's finally a GLP-1 pill, but swallowing one is not as simple as it seems. \n\n\n Taking Novo Nordisk's (NVO) Wegovy pill is an exacting process. You have to take it first thing in the morning, on an empty stomach, with no more than half a cup of water. Then you wait 30 minutes before eating breakfast, drinking coffee and other liquids, or taking other medications. You have to take the pill every day at the same time, and you must store it in the bottle (and not a pill box for travel). \n\n\n \"There's no other really big upside,\" said Diana Thiara, medical director of the University of California, San Francisco, Weight Management program. \"Why would you do something that's marginally less effective and not actually that much easier?\" \n\n\n The prevailing idea has been that a pill is easier to take, it's cheaper and it doesn't require refrigeration like Wegovy and Eli Lilly's $(LLY)$ Zepbound injections. It's also been pitched as an alternative to people who say they don't want to use an injector pen or a needle. \n\n\n But some physicians are skeptical that patients will stick with the Wegovy pill given the onerous daily regimen and comparable pricing to the Wegovy injection, especially if they end up not losing as much weight as they expect to. Instead of seeing a game-changer, these doctors view the Wegovy pill as another option in the toolbox that'll only work for certain patients. \n\n\n \"There's going to be a lot of patients that get a good benefit from it,\" said Scott Kahan, director of the National Center for Weight and Wellness in Chevy Chase, Md. \"There's also going to be quite a lot of patients that end up not using it, or try it and find the administration to be somewhat difficult, but that's OK.\" \n\n\n That said, the launch of the Wegovy pill is off to a roaring start. About 170,000 people in the U.S. had been prescribed the Wegovy pill by the first week in February, and \"most\" are paying directly for the medication, according to comments made by Novo's executives last week. Novo is charging $149 per month for the two lowest doses right now, and then the price goes up to $299 a month for the most effective doses. (The Wegovy injection costs $199 to start and then $349 to keep taking it.) \n\n\n It's the first oral GLP-1 specifically approved for weight management. GLP-1 traditionally works best in an injection, but Novo Nordisk engineered the pill using technology that it acquired in 2020 to improve how well semaglutide - the medication's active ingredient - is absorbed. \n\n\n \"This is not just a pill,\" Novo CEO Mike Doustdar said last week during an earnings call. \"It's a peptide. It's a large protein inside the pill that gives you that incredible efficacy.\" \n\n\n Demand is huge, and so are the marketing budgets. Two Super Bowl ads mentioned the Wegovy pill. Wall Street has breathlessly tracked weekly the pill's prescription volume, and the early numbers briefly lifted Novo's long-struggling stock in January. One analyst described it as the \"fastest launch ever.\" It's no wonder that Hims & Hers Health $(HIMS)$ rushed its own compounded version of the Wegovy pill to market before dropping those plans amid a legal dispute with Novo and U.S. regulators. \n\n\n Novo is facing its own clock. Lilly is gearing up to launch a new non-peptide GLP-1 pill that won't have the same administration restrictions as the Wegovy pill. Lilly also said last week that it will have a \"similar\" entry price. The Food and Drug Administration is set to decide whether to approve Lilly's orforglipron by sometime this summer. Novo Nordisk did not immediately respond to a request for comment. \n\n\n For now, patients are still trying to figure out if it's right for them. On Reddit, they are trading tips about how to handle the regimen, whether that's setting an early alarm, taking the pill, and going back to bed for 30 minutes, or asking how to relieve acid reflux from the pill if they do go back to bed. \n\n\n \"It's not an easy pill to take,\" said Scott Isaacs, an endocrinologist at Grady Memorial Hospital in Atlanta. \"It's this regime that can be onerous, and then when people learn about that, they say, 'Well, maybe taking a shot once a week is easier.'\" \n\n\n Novo sells another semaglutide pill called Rybelsus that's approved to treat type 2 diabetes with similar requirements around administration. Some experts are now taking a second look at that data to better understand what adherence to the Wegovy pill could look like. \n\n\n \"I do know - from my experience prescribing Rybelsus, which is basically the same thing for diabetes - it's hard to get patients to stay on it,\" Isaacs said. \"We see a lot of treatment failures, and when you assess why it's a treatment failure, most of the time it's because they're not taking the medication correctly.\" \n\n\n There is some data to back that up. The pharmacy benefit manager Prime Therapeutics published a study in 2024 that found patients who did not have diabetes and started taking Rybelsus were far less adherent to the medication than those on Ozempic and Wegovy injections. (All three drugs are made with semaglutide as the main ingredient, though they are approved for different conditions and with different doses.) \n\n\n The research compared adherence rates for people starting eight GLP-1s in 2021, though it doesn't reflect some of the broader market dynamics at play that year. Wegovy wasn't approved until the middle of 2021, and Novo was dealing with major supply issues by the end of that year. \n\n\n In general, it can be harder for some patients to adhere to a daily pill rather than a weekly injection, experts say. Adherence rates are usually lower in real life than in the closely controlled environment of clinical trials. But some prefer a daily pill over a weekly injection. \n\n\n \"If people don't follow that very explicit requirement about how to take it, you will not get the extent of the drug absorption that you need to get the full effect,\" said Pat Gleason, Prime Therapeutics' assistant vice president of health outcomes. \"You're going to end up having stayed on [the] drug for six months, but you aren't getting your 10% body weight loss that you were told you were likely to get.\" \n\n\n The pill led to an average weight loss of 13.6% in clinical trials, while the Wegovy injection produced about 15% weight loss. \n\n\n Physicians expect they will need to switch some patients on the pill over to the injectable so they can get the weight loss they're looking for. \n\n\n \"We would have no reason to say no,\" UCSF's Thiara said. \n\n\n -Jaimy Lee \n\n\n This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n (END) Dow Jones Newswires\n\n\n February 10, 2026 15:48 ET (20:48 GMT)\n\n\n Copyright (c) 2026 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"NVOX":0.6,"HMYY":0.6,"LLYZ":0.6,"LLYX":0.6,"LLY":1.85,"HIMZ":0.6,"HIMY":0.6,"NVO":1.96,"NVOH":0.6,"ELIL":0.6,"ELIS":0.6}},"isVote":1,"tweetType":1,"viewCount":104,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":53,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}